Akebia Therapeutics (NASDAQ:AKBA) Price Target Increased to $5.00 by Analysts at HC Wainwright
Akebia Therapeutics (NASDAQ:AKBA – Free Report) had its price objective hoisted by HC Wainwright from $3.75 to $5.00 in a research report report published on Friday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Separately, StockNews.com started coverage on shares of Akebia Therapeutics in a research note on Thursday, […]
More Stories
Analysts Set Alumis Inc. (NASDAQ:ALMS) Price Target at $27.50
Shares of Alumis Inc. (NASDAQ:ALMS – Get Free Report) have received an average recommendation of “Buy” from the eight analysts...
First Interstate BancSystem, Inc. (NASDAQ:FIBK) Receives $32.50 Consensus Target Price from Brokerages
Shares of First Interstate BancSystem, Inc. (NASDAQ:FIBK – Get Free Report) have earned an average recommendation of “Hold” from the...
StockNews.com Upgrades Thomson Reuters (NYSE:TRI) to “Hold”
StockNews.com upgraded shares of Thomson Reuters (NYSE:TRI – Free Report) (TSE:TRI) from a sell rating to a hold rating in...
Oak Woods Acquisition Co. (NASDAQ:OAKUW) Sees Significant Decline in Short Interest
Oak Woods Acquisition Co. (NASDAQ:OAKUW – Get Free Report) was the recipient of a significant drop in short interest in...
PIMCO Municipal Income Fund III (NYSE:PMX) Short Interest Down 24.4% in October
PIMCO Municipal Income Fund III (NYSE:PMX – Get Free Report) was the recipient of a large decrease in short interest...
Enstar Group Limited (NASDAQ:ESGRO) Short Interest Update
Enstar Group Limited (NASDAQ:ESGRO – Get Free Report) saw a large drop in short interest during the month of October....